Great News: GS-441524 Is Now Legally Available!

Since June 2024, GS-441524 is legally available from US compounding pharmacies by veterinary prescription. Oral tablets are now first-line treatment. Ask your vet to prescribe from Stokes Pharmacy, Wedgewood, or other licensed compounding pharmacies.

Over 20,000 cats treated with Bova GS-441524 worldwide. 78–96% survival in clinical studies.

This site is now a read-only archive. FIPLog.com operated 2020–2025. This site no longer accepts new data.
This page summarized data logged by FIPLog users during active treatment of their cats with GS-441524 (2020–2025). As the data was user-entered, it may be prone to error. Nonetheless, it provided useful estimates for what to expect when treating FIP.
This site is no longer collecting new data. The statistics below reflect the final dataset as of when the site was archived. With GS-441524 now available through regulated compounding pharmacies with veterinary oversight, treatment outcomes are expected to improve further due to consistent drug quality, proper veterinary monitoring, and standardized dosing protocols.
Final Treatment Outcomes (Archived Data)

The cats tracked on this site showed strong recovery outcomes consistent with published clinical studies:

  • Published clinical studies using regulated GS-441524 report 78–96% survival rates
  • A 2025 Dutch study of 127 cats found 78% overall survival, with 100% for ocular FIP
  • A study of 307 cats found 88.6% alive at end of initial treatment
  • Cats surviving the first 48 hours of treatment had 96% survival to 6 months

The weight gain model derived from this site's data was used in the cost estimator:
Percent Change from Start = 0.003578 × [treatment day] + (-0.0787) × [starting weight] + 0.111 × [cat age]

Key Observations from Logged Data
  • Most cats showed rapid clinical improvement within the first week of GS-441524 treatment
  • Weight gain was typical throughout treatment, with cats steadily returning to healthy weight
  • Most logged cats were under 2 years of age, consistent with FIP's prevalence in young cats
  • Dry FIP cases frequently had neurological involvement, supporting higher starting doses (10+ mg/kg)
  • Cat owners rated their cats' wellbeing on a 1–5 scale; average scores improved significantly by week 2–3
  • Relapses, when they occurred, typically happened within the first 3–84 days after stopping treatment
What This Means Today

The data collected on FIPLog helped demonstrate that GS-441524 was effective even when sourced from unregulated overseas suppliers. Now that regulated, quality-tested formulations are available from compounding pharmacies, outcomes are expected to be even better. The key improvements include: